NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm

Core Viewpoint - Nektar Therapeutics is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding the REZOLVE-AA trial, which may have impacted the trial's integrity and results [2]. Group 1: Class Action Details - Shareholders who purchased shares of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025, and December 15, 2025, are encouraged to contact the Gross Law Firm for potential lead plaintiff appointment [2]. - The allegations state that the defendants failed to disclose that enrollment in the REZOLVE-AA trial did not adhere to applicable instructions and protocol standards, which could significantly affect the trial's outcomes [2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is May 5, 2026 [3]. Group 2: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights who have suffered losses due to deceit and illegal business practices [4]. - The firm aims to ensure that companies engage in responsible business practices and seeks recovery for investors affected by misleading statements that led to artificial inflation of stock prices [4].